CPIX

Over the past six months, Cumberland Pharmaceuticals experienced several significant stock events. On July 1, 2026, the company closed a strategic transaction with Apotex Health, selling its branded commercial drug portfolio for $100 million cash plus $11 million for inventory and transition services, leading to a special dividend of $1.50 per share announced on July 13, 2026, which caused a 10.29% stock increase. The company is now transitioning to a development-stage biopharmaceutical company. On August 4, 2026, Q2 2026 financial results showed an adjusted loss of $0.20 per share and revenue of $0.17 million, missing consensus estimates, causing an initial rise followed by an 8.11% after-hours drop. On August 28, 2026, a delay was announced for the release of long-term safety and efficacy data from the Phase 2 FIGHT DMD trial for ifetroban. On September 11, 2026, the company shifted to 3-year advisory votes on executive pay. The stock price has increased by 121.1% over the past year, and as of September 24, 2026, CPIX shares crossed above their 200-day moving average, reaching $8.34 before closing at $7.94, despite a negative 'Sell' consensus rating from analysts.